Once-daily treatment may reduce Parkinson’s off time, study finds
The 150 mg dose of solengepras (CVN424), Cerevance ’s investigational oral treatment for Parkinson’s disease , significantly reduced average daily off time — periods when symptoms reappear despite medication — compared with placebo, according to topline results from a Phase 3 trial. The Phase 3 ARIS
Source: Parkinson's News Today.